CTOs on the Move

Frequency Therapeutics

www.frequencytx.com

 
Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the controlled activation of progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. Our lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 30 million people in the U.S. alone.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Dan O'Neill
Vice President of Information Technology Profile
Jeff Hrkach
Senior Vice President of Technology Development Profile

Funding

Frequency Therapeutics raised $32M on 04/17/2017
Frequency Therapeutics raised $60M on 01/07/2019
Frequency Therapeutics raised $62M on 07/23/2019
Frequency Therapeutics raised $42.3M on 07/17/2020

Similar Companies

BioBuzz

Biotech and Life Science News, Jobs, and Events for the BioHealth Capital Region - Maryland, D.C., and Virginia. BioBuzz: Be More Connected.

Verona Pharma

Verona Pharma is a clinical stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.

Spero Therapeutics

Spero is a multi-asset, clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts dedicated to identifying, developing and commercializing novel treatments focused on unmet needs of patients with multidrug-resistant (MDR) bacterial infections. Spero`s lead product candidate, SPR994, is designed to be the first broad-spectrum oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. Spero also has a platform technology known as its Potentiator Platform that it believes will enable it to develop drugs that will expand the spectrum and potency of existing antibiotics, including formerly inactive antibiotics, against Gram-negative bacteria. Spero`s lead product candidates generated from its Potentiator Platform are two intravenous, or IV,-administered agents, SPR741 and SPR206, designed to treat MDR Gram-negative infections in the hospital setting. Spero is also advancing SPR720, its novel oral therapy product candidate designed for the treatment of pulmonary non-tuberculous mycobacterial infection.

Tanox

Tanox, Inc. is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

bioStrategies Group

bioStrategies Group is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.